Kaitai Capital

Kaitai Capital, established in 2009 and located in Huangzhou, China, is a professional investment management organization focused on innovative and industrial investments, as well as wealth management. The firm primarily targets sectors such as biopharma, healthcare services, agriculture technology, consumer businesses, digital technology, and information technology. Through its diverse investment strategy, Kaitai Capital aims to identify and support promising opportunities across these industries.

Nannan Chang

Senior Investment Manager

Jin Qi

Managing Partner

Xian Li

Partner

Li Xianxian

Managing Partner

88 past transactions

Paradromics

Venture Round in 2022
Paradromics is building a high data-rate brain computer interface (BCI) to provide technology solutions for people with neurological and brain-related conditions.

Worg Pharmaceuticals

Series B in 2022
Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergies and other diseases. The company is building a pipeline for allergy and autoimmune diseases based on two technology platforms, PCFiT and Apitope, through internal development and external collaboration with flexible business models. Worg is also developing a platform for molecular allergy diagnosis.

Apache DolphinScheduler

Angel Round in 2022
Apache DolphinScheduler is a distributed and extensible workflow scheduler platform with powerful DAG visual interfaces.

Yiwise

Series B in 2022
Yiwise is a research and development artificial intelligence company specializing in NLP (Natural Language Processing) human-computer interaction. The primary business of the company is based on human-computer dialogue interaction technology, and it assists enterprises in reaching and serving their million-level members with thousands of people, as well as realizing refined and intelligent operations. Yiwise provides AI capabilities and in-depth scene-based intelligent services to customers and users.

Worktile

Series C in 2022
Worktile is a life management tool that uses lightweight notes to provide task management, collaboration, and a cool tablet experience. It helps in linking tasks, communication, documents, and other work scenarios.

Pleryon Therapeutics

Seed Round in 2022
Pleryon is a drug delivery platform company dedicated to improving the standard of living across the global community by developing programs utilizing advanced drug delivery technologies. Pleryon's platform is supported by pillar technologies and covers a broad spectrum of molecules and therapeutic areas.

Ke Ning Bio

Seed Round in 2022
Ke Ning Bio is an ophthalmic pharmaceutical manufacturer dedicated to developing ophthalmic drugs.

GluBio Therapeutics

Series A in 2022
GluBio Therapeutics focuses on molecular glue-targeted protein degradation and provides a multi-dimensional protein degradation screening platform, an innovative target validation platform, a molecular glue rational design platform, and a proprietary library of highly active molecules.

TaoCloud

Series C in 2022
TaoCloud provides intelligent software-defined storage devices and solutions to enterprise-level customers. Their long-term R&D investment and product are what really propel SDS storage. Establish the competitiveness of product technological barriers from first-generation capacity SDS 1.0 to second-generation performance-extreme all-flash SDS 2.0, securing its position in the next generation of all-flash software-defined storage.

Junsai Shengwu

Series A in 2022
Junsai Shengwu developes therapies for new solid tumor cell.
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.

Ceram Pharmaceuticals

Series A in 2022
Ceram Pharmaceuticals is a biotech firm that uses epigenetics to carry out R&D of drugs and diagnostic treatments for cancer and diseases.

Bichen Pharmaceutical

Series B in 2022
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.

West Lake Xinchen

Angel Round in 2021
West Lake Xinchen is an AI psychological service technology company, committed to creating an inclusive, scientific, intelligent and professional AI psychological service platform, and insisting on providing customers with scientific and rigorous psychological services.

CirCode

Seed Round in 2021
CirCode Bio is an innovative biotechnology company focusing on the development of circular RNA nucleic acid drugs.

Rongzhi Information

Venture Round in 2021
Rongzhi Information is a robotic process automation software developer focusing on the application of AI technology in the enterprise.

Zhiyan Technology

Series B in 2021
Zhinian Technology is a big data solution provider that develops a system with a memory-based distributed database & computing framework. The system also provides a complete set of big data process services including vector-based programming language, data query, cleaning, analysis, modeling, and visualization.

Redesign Science

Seed Round in 2021
Redesign Science is a computational chemistry company setting a new standard for early-stage, small molecule drug discovery. They efficiently simulate protein targets at the atomic level to reveal hidden, subtle drug opportunities that fall outside the capability and scope of alternative computational models.Basic science is proliferating with new understanding of biological pathways and disease mechanisms. New technologies are needed to solve emerging challenges and to commercialize new opportunities.

BioBin Data Science

Seed Round in 2021
BioBin Data Science is a new agricultural high-tech enterprise that engages in research and development management in the fields of bioinformatics and plant breeding. They created a variety of products, including breeding software, hardware, data analysis, custom development, and strategic design.

Mingsight Pharmaceuticals

Series B in 2021
Mingsight, an ophthalmic medical drug developer, has initiated a clinical trial of the original innovative drug MS-553 in patients with diabetic retinopathy. This study is the world's first clinical trial of MS-553 in this indication. In the field of CLL treatment, MS-533 can be used alone or in combination with ibrutinib, BCL-2, etc., initially showing outstanding clinical value and market potential in the treatment of patients with C481S and PLCG2 mutations; in the field of DME treatment, MS-533 can be taken orally to achieve enrichment in the retina of the fundus, avoiding the need for vitreous injection of drugs such as ranibizumab, and clinical data such as BCVA/CRT of patients also initially show the efficacy of the product.

Axbio

Series B in 2021
Axbio manufactures next-generation gene sequencing and diagnostic high-end equipment and providing complete industrial solutions.

Ai Industry

Series A in 2021
Ai Industry provides cosmetic product development and supply chain management services. They ensure the environmental sustainability of the overall solution and provide customers with real-time data on the end-to-end life cycle of the product.

Hongyun Biotech

Series B in 2021
Hongyun Biotech is a biotech company that promotes therapeutic innovation based on structural pharmacology.

Rgenta Therapeutics

Seed Round in 2021
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

BridGene Biosciences

Series A in 2021
BridGene Biosciences is a biotechnology company using cutting-edge chemoproteomic technology to discover and develop small molecules. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.

Elevoc

Series B in 2021
Elevoc is an AI-powered audio solution provider on a mission to help people hear and be heard. The company's research led to the development of its deep learning-based voice enhancement solution, which is used on millions of devices worldwide. It is the world's first real-time, deep learning-based speech enhancement solution for smart devices and communication applications that extracts speech from background noise, improves voice clarity, and improves speech intelligibility.

PackGene Biotech

Series C in 2021
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions.

Teon Therapeutics

Series A in 2021
Teon Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing a focused portfolio of small molecules that inhibit the immunosuppressive and cancer-promoting signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that will enter Phase1b trials in 2021.

Exegenesis Bio

Series B in 2021
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Worg Pharmaceuticals

Series A in 2021
Worg Pharmaceuticals is a clinical-stage biopharmaceutical company developing new treatments for allergies and other diseases. The company is building a pipeline for allergy and autoimmune diseases based on two technology platforms, PCFiT and Apitope, through internal development and external collaboration with flexible business models. Worg is also developing a platform for molecular allergy diagnosis.

ONL Therapeutics

Series B in 2020
ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Totient

Seed Round in 2020
Totient is an AI-driven biotechnology company that leverages tertiary lymphoid structures (TLSs) to identify novel tissue-specific antigens and develop matching high-affinity antibody therapeutics. It uses machine learning and immunoinformatics technology to pull critical insights from large, complex datasets, to quickly and accurately assemble the most potent antibody candidates. The unique applicability of the Totient platform allows the company to remain flexible and develop therapeutics for cancer, autoimmune disease, infections, and viruses. It was founded in 2017 and is based in Cambridge, Massachusetts.

OncoImmune

Series B in 2020
OncoImmune is a clinical-stage biopharmaceutical company that engages in the discovery and development of biopharmaceuticals for the treatment of cancer and autoimmune disease. It has completed a Phase II clinical trial of CD24Fc for the prophylactic treatment of acute Graft versus Host Disease for leukemia patients undergoing hematopoietic stem cell transplantation and is poised to launch a pivotal trial for the indication. Oncolmmune was founded in 2000 and is based in Rockville, Maryland.
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.

LYNK Pharmaceuticals

Series A in 2020
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Rgenta Therapeutics

Seed Round in 2020
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology. Its proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glue to modulate the interactions among the spliceosome, regulatory proteins, and RNAs. Its lead programs and unique approach are unlocking the therapeutic potential of historically undruggable targets in human diseases. It was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Asieris Pharmaceuticals

Series C in 2020
Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.

F&S Pharmatech

Series B in 2020
F&S Pharmatech is a Nanjing-based pharmaceutical technology company. It provides pharmaceutical intermediates, contract manufacture organization(CMO) service, differentiated API, with intellectual property solutions and environmentally friendly chemical technology to customers in healthcare industry.

Exegenesis Bio

Seed Round in 2019
Exegenesis is going to develop new medicine based on gene therapy and focuses on China and the global market. The team consists of experienced professionals, including gene therapy drug design, preclinical studies and clinical development.

Amphivena Therapeutics

Series C in 2019
Amphivena Therapeutics is a clinical-stage immuno-oncology company that develops a platform of dual-function biologics. Its Amphivena ReSTORE platform provides dual-action biologics that relieve immune suppression and activate T cell effector function in cancer patients. The platform design integrates elements of avidity, target selectivity, and enhanced safety within a single molecule. It is also can be engineered with additional solid tumor targeting modalities to add functionality such as directed tumor cell killing. It was founded in 2012 and is headquartered in South San Francisco, California.

Forkhead BioTherapeutics

Seed Round in 2019
Forkhead Bio is harnessing the intrinsic capabilities of cell conversion and regeneration in order to develop transformative therapies that improve patients'​ lives. Our first target indication is insulin-dependent diabetes.

Gaochun Pharmaceutical

Corporate Round in 2019
Sorghum Pharmaceuticals develops small molecule targeted innovative drugs for the unmet medical needs of autoimmune diseases and tumors. In the direction of unmet medical needs in autoimmune diseases and tumors, Gaochun Pharmaceuticals is committed to creating innovative product lines with global competitive advantages by leveraging its distinctive pharmaceutical, biological and clinical capabilities.

LYNK Pharmaceuticals

Seed Round in 2019
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

Doer Biologics

Series A in 2019
Zhejiang Daoer Biotechnology Co., Ltd. is located in the high-tech business incubator of Xiasha Economic Development Zone, Hangzhou, Zhejiang Province. It is a scientific research biopharmaceutical company.

Wangbaobao

Angel Round in 2019
Wangbaoba is a oatmeal brand, and consumers can buy it through some shopping platforms

Abcuro

Venture Round in 2018
Abcuro’s mission is to develop immune-modulatory bio-therapeutics for treating both autoimmunity and cancer. They leverage the systematic target validation and clinical insights gained by their founders to identify new targets. Their intensive use of bioinformatics to interrogate the transcriptome of human disease together with ex-vivo validation in diseased tissue has uncovered new approaches to target key compartments of the immune system.

JeniVision

Corporate Round in 2018
JeniVision, are an innovative biopharmaceutical company that strives to discover advanced therapies for eye and skin diseases.

F&S Pharmatech

Series A in 2018
F&S Pharmatech is a Nanjing-based pharmaceutical technology company. It provides pharmaceutical intermediates, contract manufacture organization(CMO) service, differentiated API, with intellectual property solutions and environmentally friendly chemical technology to customers in healthcare industry.
Imperial Vision Technology provides AI vision processing services. They are based on computing and visual analysis. The building of a distributed processing architecture and a device-based collaborative product system The main business involves 5G, AI, Ultra HD video, and smart manufacturing. They provide customers with AI solutions. They include algorithms, software, and hardware products. They also provide consulting services and customized solutions for customers.

Weijian Pharmaceutical Group Co.

Corporate Round in 2018
Founded in Hangzhou and headquartered in Hong Kong, China, Weijian Pharmaceuticals is a new pharmaceutical company that promotes the development of China's pharmaceutical health industry. We are committed to bringing the world's leading health products and medical technologies to the Chinese market, providing more advanced treatments for healthcare professionals. And medical information dissemination channels; provide patients with more treatment and rehabilitation resources. Since its establishment in 2006 , they have always adhered to corporate tenet of “ maintaining life and health, enjoying the peace of life ” and adhering to the core values ​​of “ integrity, intention and innovation ” . After years of unremitting efforts, they have developed into a perfect market in the country. A company that provides services such as registration, import, distribution, and promotion of pharmaceuticals and medical devices.

ForDearMe

Series A in 2018
ForDearMe is a E-commerce Start up Based in Hangzhou.

Tekeluo Biotech

Series A in 2018
Tekeluo Biotech is a healthcare company.

Carephar

Corporate Round in 2018
Carephar provides drugs for cardiovascular and cerebrovascular, digestive, and other major and chronic diseases. They are the complete industrial chain of new drug discovery, production, and commercialization, covering all stages of new compound discovery, preparation development, clinical stage research, drug registration, and post-marketing marketing promotion.

Avenue Zhichuang

Series A in 2018
Avenue Zhichuang focuses on the research and development of security robots.

Licai Mofang

Series A in 2018
Licai Mofang is a mobile app that provides investment consulting and financial services. It is an AI-driven family financial plan customization app and also a fund management platform.

Mesoor

Seed Round in 2018
Mesoor provides an AI-powered solution for recruitment. They offer services resume parsing, job-talent matching, data integration, process management, talent automation, and data analysis.

LYNK Pharmaceuticals

Angel Round in 2018
LYNK Pharmaceuticals is a biotech company focusing on the discovery and development of novel medicines to treat oncology, immunology, and inflammatory diseases. The company was founded in 2018 and is headquartered in Hangzhou, Zhejiang, China.

U Voice

Series A in 2018
U Voice is engaged in research, development, and application of intelligent voice interaction technology. It has a series of core technologies, such as speech recognition, voiceprint recognition, and natural language processing. They provide solutions for far-field intelligent voice control modules, vehicle voice control, and intelligent robot voice interaction.

Ling Miao Keji

Series A in 2018
Ling Miao Keji is an intelligent dialogue and interaction platform. They explore the technology of the algorithm layer, cognitive layer, perception layer, and platform layer and continue to provide users with stable services. Ling Miao Keji offers voice recognition and voice interaction solutions.

Chance Pharmaceuticals

Series A in 2018
Chance Pharmaceuticals provides, discovers, develops, and commercializes inhalation therapies for the world’s debilitating diseases such as chronic obstructive pulmonary disease, asthma, pulmonary arterial hypertension, and central nervous system disorders.

Asieris Pharmaceuticals

Series B in 2017
Asieris Pharmaceuticals is a Chinese biotech company focusing on therapeutic areas in oncology and multidrug-resistant infections.

Sanbo Brain Hospital

Series A in 2017
Sanbo Brain Hospital is a Beijing-based chain hospital company. It operates six brain hospitals in Beijing, Chongqing, Kunming, Fuzhou and Jinan.
New Tranx Information Technology is a Chinese artificial intelligence-powered translation company. Its products include online instant translation, computer-assisted translation, and localization services for web portals, present with translation capabilities in 37 languages.

Dengta

Series A in 2017
Dengta offers investment and financial services. The company focuses on the online finance sector of securities. Dengta develops better and more reliable mobile finance for users by fusing internet technology and expert financial services. Dengta's team has more than 10 years of experience in the fields of mobile Internet, search engines, and financial software. The team has established close working relationships with renowned wealth management, securities, and financial information system firms.

Niuniuqiche

Series A in 2017
Niuniuqiche is an e-commerce platform for new car transaction based in Shanghai, Shanghai, China.

Astrocyte Pharmaceuticals

Seed Round in 2017
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain injury patients. The company is committed to proving the neuroprotective benefits of selective astrocyte activation and advancing breakthrough therapeutic agents for treating brain injury resulting from stroke, TBI, concussion, and neurodegenerative disorders such as Alzheimer’s disease.
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.

Tree Fintech

Series A in 2017
Tree Fintech is an online platform that provides credit loan services.

Crabyter

Series B in 2016
Crabyter is a data company focusing on clinical research. They develop a clinical scientific research data management platform known as Crabyter Scientific Research Bao. Their product line includes CrabDB Scientific Research Bao Database, CrabEDC Scientific Research Bao EDC, and CrabSTAT Easy Statistics.

SEECOME

Angel Round in 2016
SEECOME is a corporation that integrates new antibacterial materials with scientific and technological innovation, functional textile research and development, and sales. Their division of the national health industry association's antibacterial branch, annual partner of fashion trends, demonstration unit for military goods and services, founder of the antibacterial and deodorant socks industry alliance, and division for deodorant sock development.

Momfo

Series A in 2016
MOMFO is a real estate lease securitization and financial services provider.

Quku Technology

Angel Round in 2016
Quku Technology is a developer of mobile games. They offer games that include crazy warrior, journey to the west, divine throne, sword spirit, deer, and ding tale.

Winturn Games

Angel Round in 2016
Winturn Games provides web platform and mobile platform of the Internet game industry. They also provide original games, spiritual duel, tribal glory, glory adventure team, and cute assi bar services.

CARsgen Therapeutics

Series B in 2016
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.

Wanli Niu

Series A in 2016
Wanli Niu provides retail solutions, data center solutions, three-party warehousing solutions, supply chain digital solutions, and business and financial integration solutions. The company helps more enterprises to reduce costs and increase efficiency and enhance digital competitiveness by continuously upgrading products and service experience. Wanli Niu aids omnichannel e-commerce in cutting expenses and boosting productivity.

U Voice

Angel Round in 2015
U Voice is engaged in research, development, and application of intelligent voice interaction technology. It has a series of core technologies, such as speech recognition, voiceprint recognition, and natural language processing. They provide solutions for far-field intelligent voice control modules, vehicle voice control, and intelligent robot voice interaction.

yundai365.com

Angel Round in 2015
yundai365.com provides e-commerce financial service in China.

Yunweikang

Series A in 2015
Yunweikang is engaged in the research and development of reflective vital sign monitoring technology and related medical products. They provide hospitals with sleep screening products and solutions. They are used in outpatients and inpatients in health checkups, ENT, neurology, respiratory, and other departments.

QY NODE

Angel Round in 2015
QY NODE produces a multi-omics and bioinformatics analysis service system that is engaged in the development of intelligent detection and precision medicine related products, multi-omics artificial intelligence system development, bioinformatics cloud application, and more. They offer a new generation of bioinformatics technology to develop multi-dimensional, multi-omics detection models and equipment to achieve intelligent detection and precision medicine.

Zdjoys.com

Venture Round in 2015
Zdjoys.com is a mobile Internet game company. They integrate research, development, and operations. They provide players with game products. They rely on the existing platform and resources. They develop and integrate the industrial chain.
Boyichuangwei Digital Media is a company based on the creation and distribution of original literary content, with IP operation and fan cultivation as the core. It is a vertical economy that integrates copyright, fan marketing, IP management, and the creation and distribution of original literary content. The production and incubation of film and television projects are included in this comprehensive digital culture and entertainment organization.

TClab

Angel Round in 2014
TClab is a medical laboratory service providing company.

NGames

Angel Round in 2013
NGames is an overseas mobile and web game developer and publisher. NGames offers a series of popular games including DDTank, League of Angels, Global Strike, Dynasty War, etc. NGames also offers gamer gifts, game strategies, and high-quality game services.

ZOCAI

Venture Round in 2011
ZOCAI offers jewelry products that include platinum diamond rings and wedding rings. They allow consumers to directly buy goods or services from a seller over the internet using a web browser or a mobile app. Their products serve consumers.

9LINK

Angel Round in 2010
9LINK is a high-tech enterprise specializing in R&D, production and sales of smart hotels and smart home products.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.